546 related articles for article (PubMed ID: 18533764)
21. The use of atypical antipsychotics after traumatic brain injury.
Elovic EP; Jasey NN; Eisenberg ME
J Head Trauma Rehabil; 2008; 23(2):132-5. PubMed ID: 18362767
[No Abstract] [Full Text] [Related]
22. Efficacy of atypical antipsychotics in elderly patients with dementia.
Tariot PN; Profenno LA; Ismail MS
J Clin Psychiatry; 2004; 65 Suppl 11():11-5. PubMed ID: 15264966
[TBL] [Abstract][Full Text] [Related]
23. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
[TBL] [Abstract][Full Text] [Related]
24. Atypical antipsychotics: newer options for mania and maintenance therapy.
Vieta E; Goikolea JM
Bipolar Disord; 2005; 7 Suppl 4():21-33. PubMed ID: 15948764
[TBL] [Abstract][Full Text] [Related]
25. Pharmacology of antipsychotics in the elderly: a focus on atypicals.
Finkel S
J Am Geriatr Soc; 2004 Dec; 52(12 Suppl):S258-65. PubMed ID: 15541166
[No Abstract] [Full Text] [Related]
26. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
27. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
Lublin H; Haug HJ; Koponen H; Sigmundsson T; Kolb SA
World J Biol Psychiatry; 2009; 10(4 Pt 3):710-8. PubMed ID: 18803070
[TBL] [Abstract][Full Text] [Related]
28. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Ballard C; Waite J
Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
[TBL] [Abstract][Full Text] [Related]
29. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases.
Croarkin PE; Emslie GJ; Mayes TL
J Clin Psychiatry; 2008 Jul; 69(7):1157-65. PubMed ID: 18572981
[TBL] [Abstract][Full Text] [Related]
30. Pharmacotherapy of irritability in pervasive developmental disorders.
Stigler KA; McDougle CJ
Child Adolesc Psychiatr Clin N Am; 2008 Oct; 17(4):739-52, vii-viii. PubMed ID: 18775367
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study.
Ishitobi M; Kosaka H; Takahashi T; Yatuga C; Asano M; Tanaka Y; Ueno K; Okazaki R; Omori M; Hiratani M; Tomoda A; Wada Y
Clin Neuropharmacol; 2013; 36(5):151-6. PubMed ID: 24045605
[TBL] [Abstract][Full Text] [Related]
32. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.
Østbye T; Curtis LH; Masselink LE; Hutchison S; Wright A; Dans PE; Schulman KA; Krishnan RR
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):407-15. PubMed ID: 15372671
[TBL] [Abstract][Full Text] [Related]
33. Optimizing atypical antipsychotic treatment strategies in the elderly.
Katz IR
J Am Geriatr Soc; 2004 Dec; 52(12 Suppl):S272-7. PubMed ID: 15541168
[No Abstract] [Full Text] [Related]
34. Akathisia and second-generation antipsychotic drugs.
Kumar R; Sachdev PS
Curr Opin Psychiatry; 2009 May; 22(3):293-99. PubMed ID: 19378382
[TBL] [Abstract][Full Text] [Related]
35. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.
Gao K; Ganocy SJ; Gajwani P; Muzina DJ; Kemp DE; Calabrese JR
J Clin Psychiatry; 2008 Feb; 69(2):302-9. PubMed ID: 18211129
[TBL] [Abstract][Full Text] [Related]
36. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Lobos CA; Kissling W; Davis JM; Leucht S
Schizophr Res; 2010 Nov; 123(2-3):225-33. PubMed ID: 20692814
[TBL] [Abstract][Full Text] [Related]
37. The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania.
Keck PE
J Clin Psychiatry; 2005; 66 Suppl 3():5-11. PubMed ID: 15762829
[TBL] [Abstract][Full Text] [Related]
38. Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.
Awad G; Hassan M; Loebel A; Hsu J; Pikalov A; Rajagopalan K
BMC Psychiatry; 2014 Feb; 14():53. PubMed ID: 24559217
[TBL] [Abstract][Full Text] [Related]
39. [Augmentation of antidepressants with atypical antipsychotics in non-delusional unipolar depressed patients with non-response to antidepressant-monotherapy].
Erbe S; Gutwinski S; Bschor T
Psychiatr Prax; 2012 Mar; 39(2):57-63. PubMed ID: 22189902
[TBL] [Abstract][Full Text] [Related]
40. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
van Winkel R; De Hert M; Wampers M; Van Eyck D; Hanssens L; Scheen A; Peuskens J
J Clin Psychiatry; 2008 Mar; 69(3):472-9. PubMed ID: 18348593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
